Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( (JP:4597) ) has provided an update.

Solasia Pharma has updated investors on the status of its key pipeline and marketed products alongside its 2025 financial results, highlighting progress in commercialization and regional partnerships. In China, sales of Sancuso for chemotherapy-induced nausea and vomiting are now led by Lee’s Pharmaceutical following Solasia’s exit from direct sales, and a new license deal with MAAB will shift manufacturing and marketing rights across Greater China with commercial rollout targeted for 2027, supported by fresh Phase III data showing superiority over palonosetron.

For its oncology therapy DARVIAS, approved in Japan for relapsed or refractory peripheral T-cell lymphoma, Solasia is expanding its global reach through licensing in South America and Eastern Europe, where new NDAs have been filed or accepted and a fresh MAP-based commercialization agreement has been signed. The company is also pursuing indication expansion into EBV-positive B-cell lymphoma and breast cancer, and continues to invest in earlier-stage nucleic acid, gene therapy, antibody modification, and diagnostic probe projects, underscoring a strategy to broaden its oncology pipeline and strengthen long-term growth prospects.

The most recent analyst rating on (JP:4597) stock is a Hold with a Yen29.00 price target. To see the full list of analyst forecasts on Solasia Pharma KK stock, see the JP:4597 Stock Forecast page.

More about Solasia Pharma KK

Solasia Pharma K.K. is a Japan-based specialty pharmaceutical company focused on oncology and supportive care, developing and commercializing drugs and medical devices for cancer-related indications. Its portfolio includes products for chemotherapy-induced nausea and vomiting, peripheral T-cell lymphoma, oral mucositis pain, and chemotherapy-induced peripheral neuropathy, with a geographic focus on Asian markets and selective global partnerships.

Average Trading Volume: 39,327,437

Technical Sentiment Signal: Sell

Current Market Cap: Yen8.6B

Learn more about 4597 stock on TipRanks’ Stock Analysis page.